Professor Quentin Qiang Liu
Institute of cancer stem cell, Dalian Medical University
Time：2016.1.21 (Thursday) 9:00am
Location: 406 Room, Biotechnology Division, Dalian Institute of Chemical Physics
Introduction：
Prof. Liu obtained his M.D. in Medical and Ph.D in Immunology/Cell Biology at University of Illinois. As the director of the institute of cancer stem cell, he dedicates to study the regulatory mechanisms and pathways involved in cancer initiation, progression and molecular targeted therapy. In view of his efforts and contribution to the field, Prof. Liu receives many honors and awards, including the Innovation of Science and Technology Talent of Science and Technology Ministry, Chief Scientist of Major State Basic Research Development Program (973), State Class Talents of National Talents Engineering of Ministry of Personnel, Outstanding Talents of Cultivation Plan of Liaoning Province Natural Science Foundation, The Second Prize of Science of China Anti-Cancer Association, Fellow of American Institution of Medical and Biological Engineering (AIMBE), the Chinese Medicine Foundation (CMB) Distinguished Professor Award.
Professor Liu’s group focuses on three objectives: (A) to study the molecular targeted therapy; (B) to study the signaling transduction in cancer stem cells; (C) to study the tumor epigenetic and differentiation inducing therapy. Prof. Liu has published several important papers in J. Clin. Oncol., Nat Commun, Autophagy, Blood et al.
Abstract：
The Aurora kinase family comprises three serine/threonine kinases, Aurora-A, -B, and -C, which play key roles in mitosis. Over-expression or gene amplification of Aurora kinases has been reported in a wide range of different human malignancies, and Aurora kinases have emerged as oncogenes involved in tumorigenesis. Hence, Aurora kinases represent promising targets for anti-cancer drug development. A number of Aurora kinase inhibitors (AKIs) have been discovered and are undergoing clinical trials. Recent studies have identified new functions of Aurora kinases during cancer development and have explored the mechanisms underlying the anticancer effects of AKIs. Here, we discuss the most recent advances in Aurora kinase-targeted cancer therapy, with a focus on the cancer-related roles of Aurora kinases, the signaling mediated by Aurora kinases, the cellular substrates of Aurora kinases that have been linked to tumorigenesis, preclinical and clinical AKI data, and alternative routes of Aurora kinase inhibition.
Contact：1809 Group Lu Wang（9620）